- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04650581
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)
March 4, 2024 updated by: Canadian Cancer Trials Group
Double-Blind Placebo-Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Patients enrolled in this study will receive either Ipatasertib plus Fulvestrant or placebo (a substance that looks like the study drug but does not have any active or medicinal ingredient) plus Fulvestant.
The study will provide information about the ability of Ipatasertib plus Fulvestrant to control the cancer, the side effects and safety of the treatment, how patients feel while taking the treatment and associated costs.
Study Type
Interventional
Enrollment (Estimated)
250
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wendy Parulekar
- Phone Number: 613-533-6430
- Email: wparulekar@ctg.queensu.ca
Study Locations
-
-
-
Garran, Australia, ACT 2605
- Suspended
- Canberra Hospital
-
Herston, Australia, 4029
- Suspended
- Royal Brisbane and Womens Hospital
-
-
New South Wales
-
Bowral, New South Wales, Australia, 2576
- Suspended
- Southern Highlands Cancer Centre
-
Gateshead, New South Wales, Australia, 2324
- Suspended
- Lake Macquarie Private Hospital
-
Gosford, New South Wales, Australia, 2250
- Suspended
- Gosford Hospital
-
Macquarie University, New South Wales, Australia, 2109
- Recruiting
- Macquarie University Hospital
-
Contact:
- Dhanusha Sabanathan
-
Nowra, New South Wales, Australia, 2541
- Suspended
- Shoalhaven Cancer Care Centre
-
-
Queensland
-
Birtinya, Queensland, Australia, 4575
- Suspended
- Sunshine Coast University Hospital
-
Toowoomba, Queensland, Australia, 4350
- Recruiting
- Toowoomba Hospital
-
Contact:
- Bhaskar Karki
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
- Suspended
- Victorian Breast and Oncology Care
-
Epping, Victoria, Australia, 3076
- Suspended
- The Northern Hospital
-
Frankston, Victoria, Australia, 3199
- Recruiting
- Frankston Hospital
-
Contact:
- Jacqui Thomson
- Phone Number: 3 5976-0812
-
Melbourne, Victoria, Australia, 3004
- Not yet recruiting
- Alfred Hospital
-
Contact:
- Maggie Moore
-
St. Albans, Victoria, Australia, 3021
- Suspended
- Sunshine Hospital
-
-
Western Australia
-
Bunbury, Western Australia, Australia, 6230
- Suspended
- St John of God Bunbury
-
Murdoch, Western Australia, Australia, 6150
- Suspended
- Fiona Stanley Hospital
-
-
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 5L3
- Suspended
- BCCA - Cancer Centre for the Southern Interior
-
Surrey, British Columbia, Canada, V3V 1Z2
- Suspended
- BCCA - Fraser Valley Cancer Centre
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Recruiting
- BCCA - Vancouver Cancer Centre
-
Contact:
- Stephen Chia
- Phone Number: 2752 604 877-6000
-
-
New Brunswick
-
Saint John, New Brunswick, Canada, E2L 4L2
- Not yet recruiting
- Regional Health Authority B, Zone 2
-
Contact:
- Margot Burnell
- Phone Number: 506 648-6884
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- Recruiting
- QEII Health Sciences Centre
-
Contact:
- Daniel Rayson
- Phone Number: 902 473-6106
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- Suspended
- Royal Victoria Regional Health Centre
-
Brampton, Ontario, Canada, L6R 3J7
- Recruiting
- William Osler Health System
-
Contact:
- Margaret Balcewicz
- Phone Number: 572643 905 494-2120
-
Hamilton, Ontario, Canada, L8V 5C2
- Suspended
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Kingston, Ontario, Canada, K7L 2V7
- Suspended
- Kingston Health Sciences Centre
-
London, Ontario, Canada, N6A 5W9
- Recruiting
- London Regional Cancer Program
-
Contact:
- Jacques Antoun Raphael
- Phone Number: 519 685-8640
-
Newmarket, Ontario, Canada, L3Y 2P9
- Suspended
- Stronach Regional Health Centre at Southlake
-
Ottawa, Ontario, Canada, K1H 8L6
- Recruiting
- Ottawa Hospital Research Institute
-
Contact:
- Terry Ng
- Phone Number: 613 737-7700
-
Sault Ste. Marie, Ontario, Canada, P6B 0A8
- Suspended
- Algoma District Cancer Program
-
Thunder Bay, Ontario, Canada, P7B 6V4
- Suspended
- Thunder Bay Regional Health Sciences Centre/
-
Toronto, Ontario, Canada, M5G 2M9
- Suspended
- University Health Network
-
Windsor, Ontario, Canada, N8W 2X3
- Suspended
- Windsor Regional Cancer Centre
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Suspended
- Centre Integre de Sante et de Services Sociaux
-
Montreal, Quebec, Canada, H2X 3E4
- Recruiting
- CHUM-Centre Hospitalier de l'Universite de Montreal
-
Contact:
- Jean-Pierre Ayoub
- Phone Number: 20692 514 890-8000
-
Quebec City, Quebec, Canada, G1S 4L8
- Suspended
- CHA-Hopital Du St-Sacrement
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Suspended
- Allan Blair Cancer Centre
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Suspended
- Saskatoon Cancer Centre
-
-
-
-
-
Auckland, New Zealand, 1023
- Suspended
- Auckland City Hospital
-
Wellington, New Zealand, 2
- Suspended
- Wellington Cancer Centre, Wellington Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically and/or cytologically confirmed ER positive, HER-2 negative breast cancer
- Female patients must be post-menopausal; female patients who are pre-menopausal must have ovarian suppression using LHRH agonist while on study
- Clinical and/or radiographic progression during treatment with or within 28 days after discontinuation of first line of treatment with a CDK 4/6 inhibitor and an aromatase inhibitor (AI) for advanced/metastatic disease
- Evidence of clinically and/or radiologically documented disease
- ≥ 18 years of age
- ECOG performance status of 0 or 1
No concurrent anti-cancer therapy and must satisfy the following criteria for previous therapy
- Must not have received more than one prior line of treatment with a CDK 4/6 inhibitor and an AI in the advanced disease setting.
- Treatment with CDK 4/6 inhibitor and AI must have been the most recent treatment prior to registration for this study
Adequate hematology and organ function, in the absence of growth factors
- Absolute neutrophils > 1.5 x 10^9/L
- Platelets ≥ 100 x 10^9/L
- Hemoglobin > 90 g/L
- Total Bilirubin ≤ 1.5 x ULN (upper limit of normal) or ≤ 3 x ULN if confirmed Gilbert's Syndrome
- ALT and AST ≤ 2.5 x ULN (or ≤ 5.0 x ULN if liver or bone metastasis)
- Alkaline phosphatase ≤ 2.0 x ULN (or ≤ 5.0 x ULN if liver metastases, ≤ 7.0 x ULN if bone metastasis)
- Fasting glucose ≤ 8.3 mmol/L
- HbA1c ≤ 7.5%
- Serum albumin ≥ 30 g/L
- INR ≤ 1.2
- Serum Creatinine or Creatinine clearance ≤ 1.5 x ULN or ≥ 50 mL/min; measured directly by 24-hour urine sampling or as calculated by Crockcroft and Gault equation
Exclusion Criteria:
- Untreated or symptomatic CNS metastases, radiation treatment for CNS metastases within 28 days
- Active inflammatory bowel disease, bowel inflammation, inability to swallow oral medication or GI condition that alters oral absorption
- Prior treatment with fulvestrant, selective estrogen receptor degraders (SERDs) or known inhibitors of the PI3K pathway including PI3K inhibitors, AKT inhibitors, or mTOR inhibitors
- Mean QT interval corrected for heart rate (QTc) ≥ 480 msec by ECG or history of familial long QT syndrome
- Active or uncontrolled infections or serious illnesses or medical conditions
- Clinically significant liver diseases
- History of lung disease or history of opportunistic infections
- Type 1 or Type 2 diabetes mellitus requiring insulin
- Grade ≥ 2 uncontrolled hypercholesterolemia or hypertriglyceridemia
- Known abnormalities in coagulation
- History of hypersensitivity to the study drugs or components
- Pregnant or lactating women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
500 mg IM cycle 1 days 1 and 15 followed by 500 mg IM day 1 q 28 days subsequent cycles
PO QD days 1-21 every 28 days
|
Experimental: Ipatasertib + Fulvestrant
|
400 mg PO QD days 1-21 every 28 days
500 mg IM cycle 1 days 1 and 15 followed by 500 mg IM day 1 q 28 days subsequent cycles
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free survival (PFS) using RECIST 1.1
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival (OS)
Time Frame: 5 years
|
5 years
|
To compare the two treatment arms with respect to investigator assessed PFS (per RECIST 1.1) in the PIK3CA/AKT1/PTEN altered cohort
Time Frame: 5 years
|
5 years
|
Investigator assessed PFS (per RECIST 1.1) in the PIK3CA/AKT1/PTEN non-altered cohort
Time Frame: 5 years
|
5 years
|
PFS as assessed by blinded central radiology review in all enrolled patients, PIK3CA/AKT1/PTEN altered and non-altered cohorts
Time Frame: 5 years
|
5 years
|
Response rate (RR) (per RECIST 1.1)
Time Frame: 5 years
|
5 years
|
Duration of Response (DoR)
Time Frame: 5 years
|
5 years
|
Clinical Benefit Rate (CBR);
Time Frame: 5 years
|
5 years
|
Time to commencement of subsequent line of systemic therapy or death (TSST)
Time Frame: 5 years
|
5 years
|
Number of participants with treatment-related adverse events as assessed by CTCAE version 5.0
Time Frame: 5 years
|
5 years
|
Quality of Life (QOL) as measured using EORTC QLQ-C30 questionnaire
Time Frame: 5 years
|
5 years
|
Adverse events as measured using NCI PRO-CTCAE questionnaire
Time Frame: 5 years
|
5 years
|
Economic Evaluation of healthcare utilization using average cost per study subject by treatment arm to estimate an overall mean cost per study arm.
Time Frame: 5 years
|
5 years
|
Economic Evaluation of health utilities measured using EQ-5D-5L
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Stephen Chia, BCCA - Vancouver Cancer Centre, BC Canada
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 27, 2021
Primary Completion (Estimated)
June 30, 2024
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
November 24, 2020
First Submitted That Met QC Criteria
December 1, 2020
First Posted (Actual)
December 2, 2020
Study Record Updates
Last Update Posted (Estimated)
March 5, 2024
Last Update Submitted That Met QC Criteria
March 4, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protein Kinase Inhibitors
- Hormone Antagonists
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Fulvestrant
- Ipatasertib
Other Study ID Numbers
- MA40
- 2101 (Other Identifier: BCT)
- M041883 (Other Identifier: Hoffmann-LaRoche Ltd.)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
Clinical Trials on Ipatasertib
-
Genentech, Inc.CompletedHealthy VolunteerUnited States
-
Genentech, Inc.Completed
-
Hoffmann-La RocheCompleted
-
Genentech, Inc.CompletedHepatic InsufficiencyUnited States
-
Genentech, Inc.Completed
-
Institute of Cancer Research, United KingdomHoffmann-La RocheRecruitingSolid Tumor | Glioblastoma Multiforme | Prostate Cancer MetastaticUnited Kingdom
-
SOLTI Breast Cancer Research GroupRoche Pharma AGRecruitingMetastatic Breast CancerSpain
-
Jun Zhang, MD, PhDUniversity of Iowa; University of KentuckyRecruitingNSCLC Stage IV | NSCLC Stage IIIBUnited States
-
Hoffmann-La RocheRecruitingCancerKorea, Republic of, United Kingdom, Japan, Costa Rica, Belgium, Taiwan, Russian Federation, Mexico, Poland, France
-
Hoffmann-La RocheCompletedTriple-Negative Breast CancerIsrael, United States, Australia, Korea, Republic of, Belgium, Argentina, Denmark, Finland, Italy, Portugal, Spain, Taiwan, Thailand, Japan, United Kingdom, Brazil, Canada, Colombia, Mexico, France, Costa Rica, Switzerland, Czechia, P... and more